Decision Time For MSD/AZ, Lilly, Kite EU Fast-Track Hopes
Executive Summary
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.
You may also be interested in...
AstraZeneca/MSD’s Koselugo Among 14 New Hopefuls At EMA
New drugs from Eli Lilly, Pfizer, Janssen, GSK, Arvelle, BioCryst, Diurnal and Myovant are also among the latest products the European Medicines Agency is evaluating for potential pan-EU approval.
EU Speedy Review Success For Kite But Not For Lilly
KTE-X19, Kite’s potential new CAR-T therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib
Fast-Track Fail For Kite’s KTE-X19 EU Review?
Priority review is likely in the US for Kite’s second CAR-T therapy offering but it seems the company will have to make do with standard review in the EU.